Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy
Publication year: 2020
WHO estimates that in 2015, 257 million people were living with chronic hepatitis B
virus (HBV) infection worldwide, and that 900 000 had died from HBV infection, mostly
as a result of cirrhosis or hepatocellular carcinoma. Most HBV-associated deaths among
adults are secondary to infections acquired at birth or in the first five years of life. In May
2016, the World Health Assembly endorsed the Global Health Sector Strategy on viral
hepatitis, which calls for the elimination of viral hepatitis as a public health threat by
2030 (defined as a 90% reduction in incidence of new infections and a 65% reduction
in mortality). Elimination of HBV infection as a public health threat requires a reduction
in the prevalence of hepatitis B surface antigen (HBsAg) to below 0.1% in children 5
years of age. This can be achieved through universal immunization of newborns against
hepatitis B and other interventions to prevent mother-to-child transmission of HBV.